Acquisitions, Investments, and Licenses - Textual (Details)	3 Months Ended			1 Months Ended	3 Months Ended									1 Months Ended			3 Months Ended				1 Months Ended	0 Months Ended										3 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2014 USD ($)	Jun. 30, 2012 SciVac Variable Interest Entity, Primary Beneficiary member	Mar. 31, 2015 SciVac Variable Interest Entity, Primary Beneficiary USD ($)	Mar. 31, 2015 Sevion	Dec. 31, 2014 Sevion	Mar. 31, 2015 Cocrystal	Dec. 31, 2014 Cocrystal	Mar. 31, 2015 ARNO	Dec. 31, 2014 ARNO	Mar. 31, 2015 Neovasc	Dec. 31, 2014 Neovasc	Jan. 31, 2014 Pharmsynthez	Apr. 30, 2013 Pharmsynthez USD ($)	Apr. 30, 2013 Pharmsynthez RUB	Mar. 31, 2015 Pharmsynthez USD ($)	Mar. 31, 2014 Pharmsynthez USD ($)	Mar. 31, 2015 Zebra	Oct. 31, 2013 Zebra Series A Preferred Stock	Oct. 31, 2013 Zebra Restricted Stock	Apr. 17, 2014 Inspiro USD ($)	Apr. 17, 2014 Inspiro USD ($)	Mar. 31, 2015 ChromaDex [Member]	Mar. 31, 2015 Rxi Pharmaceuticals Corporation [Member]	Mar. 31, 2015 Cocrystal	Mar. 31, 2015 Pharmsynthez	Mar. 31, 2015 Sevion	Mar. 31, 2015 Non-Invasive Monitoring Systems, Inc. [Member]	Mar. 31, 2015 Neovasc	Mar. 31, 2015 ARNO	Mar. 31, 2014 Other Income [Member] USD ($)	Jun. 30, 2015 Scenario, Forecast [Member]	Jun. 30, 2015 Scenario, Forecast [Member] SciVac
Business Acquisition [Line Items]
Inspiro stock purchase agreement																							100.00%
Cash paid at closing date																						$ 1,500,000
Delivery of common stock																						999,556
Common stock value																							8,600,000
Stock price																							$ 8.57
Number of trading days																						10 days
Average share price																						$ 9.00
In-process research and development																						10,100,000
Warrants to purchase common shares							100,000		1,000,000		800,000		1,000,000
Number of shares purchased															13,600,000	13,600,000
Asset Purchase Agreement															9,600,000
Number of share options received in purchase agreement															12,000,000	12,000,000
Proceeds to be received from sale of proprietary technology															8,100,000	265,000,000
Shares Received In Satisfaction of Notes Receivable														12,000,000
Deferred revenue	288,800,000		6,700,000												9,500,000
Period for development of technology															3 years	3 years
Revenue related to our license agreements																	0	500,000
Revenue collaboration agreement, offset to research and development																	200,000	400,000
Investment Owned, Balance, Shares																				840,000
Stock ownership percentage				50.00%	45.00%																													30.00%
Additional working capital					6,600,000
Number of members of board of directors				5
Number of members of board of directors appointed by reporting entity				3
Percent of board of directors appointed by reporting entity				60.00%
Shares Received As Gift																					900,000
Ownership percentage						4.00%		8.00%		4.00%		5.00%							27.00%							8.00%	17.00%	4.00%	1.00%	5.00%
Total assets of equity method investees	373,400,000
Total liabilities of equity method investees	(51,000,000)
Net losses of equity method investees	(37,800,000)
Equity Method Investment, Quoted Market Value	112,100,000
Available-for-Sale Securities, Ownership Percentage																								2.00%	10.00%						4.00%
Gain (Loss) on Sale of Investments	$ 216,000	$ 1,273,000																														$ 1,300,000
Ownership percentage by shareholder																																	68.40%